Mutations of dysferlin (Dysf), a key sarcolemma integrity protein, lead to dysferlinopathies including limb-girdle muscular dystrophy type 2B (LGMD2B) due to impaired calcium-dependent fusion of lipid patches and transmembrane protein trafficking during sarcolemma resealing after mechanical injury [2–5]. The gene discussed is DYSF; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.